Weight loss service
Sourced directly from manufacturers
Supported by UK-based clinical team with monthly check-ins
UK-based clinical expertise and monthly check-ins
There are two oral GLP-1 treatments generating excitement in the UK right now:
GLP-1 | Semaglutide
The FDA in the US has already approved oral semaglutide for weight management. UK regulatory approval is still pending, but the clinical data is promising and arrival is expected imminently.
GLP-1 | Orforglipron
Foundayo (Orforglipron) is a next-generation oral GLP-1 medicine currently in late-stage clinical trials. Unlike semaglutide, it is a small molecule that does not require the same food and water restrictions when taken.
GLP-1 (glucagon-like peptide-1) receptor agonists are a class of prescription-only medicines used to support weight management. Currently available in injectable form, following assessment by a clinician.
Oral GLP-1 tablets are being developed and studied as once-daily tablet formulations for weight management. These medicines work by mimicking the GLP-1 hormone, which can help regulate appetite and food intake.
Treatment suitability, availability and prescribing decisions are determined by a clinician following an appropriate consultation.
Tablet-based weight loss treatments
Contain a GLP-1 receptor agonist (the same active ingredient as Wegovy)
Taken once daily orally, rather than once weekly by injection
Clinically tested with results comparable to injectable options
A non-injectable alternative for those who prefer not to use a pen
Easier to fit into everyday life for some people
No refrigeration or injection equipment required
The same clinically-led approach, in a simpler format
Oral GLP-1 tablets and injectable GLP-1 treatments are both effective, clinically-proven options. The right choice depends on your personal preferences and circumstances. Here is a quick comparison:
Be the first to know when oral GLP-1 tablets are licensed for use in the UK
Clinician-led care: Receive ongoing support from Phlo's UK-registered clinical team
Trusted by thousands of patients: Holland & Barrett is powered by Phlo, a GPhC-regulated pharmacy
Expert guidance: Clinicians will help you understand whether oral GLP-1 treatment is right for you when it becomes available
Like all medicines, oral GLP-1 tablets can cause side effects. Most are digestive and tend to be mild to moderate, often settling down as your body adjusts during the first few weeks of treatment.
*This information is based on phase 3 clinical trial data and US prescribing information.This is not a complete list of side effects. Always consult a qualified clinician before starting treatment.
1. Wharton S, et al. Oral semaglutide 25mg in adults with overweight or obesity (OASIS 4). N Engl J Med. 2025;393(11):1077–1087. doi:10.1056/NEJMoa2500969
2. Wharton S, et al. Orforglipron, an oral GLP-1 receptor agonist for obesity (ATTAIN-1). N Engl J Med. 2025;393(18):1796–1806. doi:10.1056/NEJMoa2511774
3. Novo Nordisk. Wegovy (semaglutide) tablet US prescribing information. Plainsboro, NJ: Novo Nordisk Inc.; 2025. 4.Eli Lilly and Company. Foundayo (orforglipron) US prescribing information. Indianapolis, IN: Eli Lilly; 2026.
4. Eli Lilly and Company. Foundayo (orforglipron) US prescribing information. Indianapolis, IN: Eli Lilly; 2026.
Unit 1 Fifth Street
Trafford Park
Manchester
England
M17 1JX
MRPharmSGPhC
Registration Number: 2205052
Phlo Technologies Ltd
